Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing oncology and antiviral drug candidates, with its lead program centered on Annamycin, a liposomal anthracycline designed to avoid the cardiotoxicity associated with older drugs in the class. The company also advances WP1066 and related formulations through investigator-initiated and preclinical studies, while relying heavily on intellectual property, sponsored research, and external clinical partners rather than commercial sales.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAnnamycin is the company's main drug program, aimed at treating cancers with a non-cardiotoxic anthracycline approach.
WP1066 oral and IV formulations are being developed for brain cancer and other oncology settings.
WP1122-related assets and options cover potential antiviral and other therapeutic applications.
Patent filings, licenses, and sponsored research agreements support exclusivity and development rights.
Customers
Moleculin does not sell commercial products today; its primary counterparties are clinical investigators, research institutions, and licensing partners that help advance its drug candidates. Future customers would be hospitals, oncologists, and patients in oncology indications if the programs reach approval. The company also depends on academic collaborators such as MD Anderson, Northwestern University, and Emory University to generate data and de-risk development.
Universities and cancer centers buy or receive study drug and collaborate on trials to generate efficacy and safety data.
Hospitals and oncologists would use approved Annamycin or related therapies in cancer care settings.
Patients are the end beneficiaries for Annamycin and WP1066 programs targeting difficult-to-treat cancers.
Partners such as MD Anderson are important for IP access, sponsored research, and option structures.
Strategy
The company is concentrating resources on Annamycin and away from non-core WP1122 licenses, reflecting a tighter pipeline focus and a need to maximize limited capital. It is also strengthening patent protection and regulatory readiness while using external collaborators to advance clinical and preclinical work at lower internal cost. Near term, the strategy is to preserve optionality through IP, sponsored research, and trial progress rather than commercial launch.
Annamycin is the lead value driver and the most advanced program in the portfolio.
Patent exclusivity is critical for future commercialization and partnering value.
The company has limited resources and relies on collaborators to progress programs efficiently.
Geography
Moleculin is headquartered in the United States and its development activities are centered around U.S.-based research and clinical partners, including MD Anderson in Houston, Northwestern University, and Emory University. The company is also building international patent protection, including Europe and other major jurisdictions, to support future commercialization rights for Annamycin. Because it has no product revenue and no disclosed country revenue mix, geography is mainly about where research is conducted and where IP protection is being secured.
Risks
Moleculin remains a development-stage biotech with no product revenue, so its value depends on successful clinical execution, regulatory progress, and access to financing. The company also faces Nasdaq listing-compliance risk, dilution risk from warrants and future capital raises, and the usual scientific, safety, and trial-enrollment uncertainty that affects oncology drug developers. Intellectual property protection and collaboration continuity are also important because the business model depends on exclusive rights and external research partners.
- Nasdaq delisting riskImpact: HighLikelihood: High
The company disclosed non-compliance with equity and bid-price requirements.
Exposure - Financing and dilution riskImpact: HighLikelihood: High
The company expects to need additional capital and has warrant-related dilution exposure.
Exposure - Clinical development riskImpact: HighLikelihood: Medium
Drug candidates may fail to show sufficient safety or efficacy in trials.
Exposure - Regulatory riskImpact: MediumLikelihood: Low
FDA feedback and approval requirements can delay or alter development plans.
Exposure - IP and collaboration dependencyImpact: Medium
The business relies on licensed technology and external research partners.
Exposure
Accounting
Judgemental itemsThe company changed certain warrants from liability to equity accounting, affecting reported losses and comparability.
Impact: Non-cash gains/losses and equity presentation
Warrant-related fair value changes and issuance losses can create large swings in net income.
Impact: Other income/expense and earnings volatility
Clinical and preclinical costs are expensed as incurred, driving the main operating cost base.
Impact: Operating loss and cash burn
The company expects to need additional financing to continue development.
Impact: Disclosure sensitivity and capital structure analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Molecular Partners AG
MOLN · Biological Products, (No Diagnostic Substances)
Molecular Partners AG is a clinical-stage biopharmaceutical company focused on designing and developing DARPin therapeutics, a proprietary protein-drug platform.
BeyondSpring Inc.
BYSI · Pharmaceutical Preparations
Erasca, Inc.
ERAS · Pharmaceutical Preparations
Annexon, Inc.
ANNX · Pharmaceutical Preparations
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
Last updated: 24/09/2026